Thursday, August 2, 2012

INX-189 Phase II study halted due to heart failure

In the Phase 2 trial heart failure was observed in INX-189 200mg dose on top of ribavarin and PEG-interferon   As of now, it is unclear what will happen with INX-189 in other trials-and we await updates from BMY.  If INX-189 fails, BMY competitive positioning is likely to significantly weaken and the major beneficiary of this failure obviously would be Gilead.